Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

Plozasiran sodium (AROAPOC-3) is under development for the treatment of severe hypertriglyceridemia, mixed dyslipidemia and familial Chylomicronemia. It is administered through the subcutaneous route.

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Plozasiran sodium (AROAPOC-3) is under development for the treatment of severe hypertriglyceridemia, mixed dyslipidemia and familial Chylomicronemia. It is administered through the subcutaneous route.

Severe hypertriglyceridemia (≥500 mg/dl [5.65 mmol/l]) should be treated to reduce the risk of pancreatitis. The omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA ...

Light to moderate alcohol drinking can raise HDL, but heavy drinking can increase total cholesterol, LDL, and triglycerides. This raises the chance of developing cardiovascular disease. Although ...

Carbohydrates, lipids, bile acids, various inorganic salt ions and organic acids are the main nutrients or indispensable components of the human body. Dysregulation in the processes of absorption, ...

An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

Familial Mediterranean fever is an autosomal recessive genetic disorder characterized by recurrent febrile polyserositis, especially prevalent in individuals of Mediterranean descent. Familial ...